.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Daiichi Sankyo
UBS
Colorcon
Novartis
Medtronic
Merck
AstraZeneca
Chubb
Farmers Insurance

Generated: September 26, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Method of delivering powder transdermally with needless injector
Abstract:A needleless syringe having a membrane which is ruptured by gas pressure to generate a supersonic gas flow in which particles containing a therapeutic agent are injected. This provides effective transdermal delivery of the therapeutic agent.
Inventor(s): Bellhouse; Brian J. (Islip, GB2), Sarphie; David F. (Witney, GB2), Greenford; John C. (Abingdon, GB2)
Assignee: Oxford Biosciences Limited (Oxford, GB2)
Application Number:08/474,367
Patent Claims: 1. A method of therapeutic treatment, comprising transdermally delivering particles of a powdered therapeutic agent across skin tissue of a mammalian subject, said particles being delivered to the locus of transdermal administration at a velocity in the range of between 200 and 2,500 m/sec, in which the particles of the therapeutic agent have a size predominantly in the range of about 10 to 250 .mu.m and a density in the range of 0.1 to 25 g/cm.sup.3.

2. A method according to claim 1, wherein the velocity range is between 500 and 1,500 m/sec.

3. A method according to claim 2, wherein the velocity range is between 750 and 1000 m/sec.

4. A method according to claim 1, wherein the size range is between 10 and 20 .mu.m.

5. A method according to claim 1, wherein the density range is between 0.5 and 2.0 g/cm.sup.3.

6. A method according to claim 1, in which the particles of the therapeutic agent are comprised of a stable mixture of drugs which are unstable when mixed wet.

7. A method according to claim 1, wherein the therapeutic agent comprises insulin.

8. A method according to claim 1, in which the particles of the therapeutic agent are in the form of spherical shells.

9. A method according to claim 1, wherein the mammalian subject is human.

10. A method of therapeutic treatment, comprising transdermally delivering particles of a powdered therapeutic agent across skin tissue of a mammalian subject, wherein said particles have a size predominantly in the range of about 10 to 250 .mu.m and are delivered to the locus of transdermal administration at a momentum density of between 2 and 10 kg/sec/m.

11. A method according to claim 10, wherein the momentum density is between 4 and 7 kg/sec/m.

12. A method according to claim 10, wherein the mammalian subject is human.

13. A method of therapeutic treatment, comprising transdermally delivering particles of a powdered therapeutic agent combined with an inert carrier or diluent across skin tissue of a mammalian subject, said particles being delivered to the locus of transdermal administration at a velocity in the range of between 200 and 2,500 m/sec, in which the particles of the therapeutic agent have a size predominantly in the range of about 10 to 250 .mu.m and a density in the range of 0.1 to 25 g/cm.sup.3.

14. A method of therapeutic treatment, comprising transdermally delivering particles of a powdered therapeutic agent combined with an inert carrier or diluent across skin tissue of a mammalian subject, wherein said particles have a size predominantly in the range of about 10 to 250 .mu.m and are delivered to the locus of transdermal administration at a momentum density of between 2 and 10 kg/sec/m.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Dow
Teva
Cipla
Chubb
Farmers Insurance
Colorcon
Healthtrust
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot